Health economics of cardiac resynchronization therapy.
作者信息
Jolobe Oscar Mp
机构信息
Retired Geriatrician Manchester Medical Society Manchester M13 9PL.
出版信息
Br J Hosp Med (Lond). 2017 Oct 2;78(10):594. doi: 10.12968/hmed.2017.78.10.594.
PMID:29019724
Abstract
摘要
相似文献
1
Health economics of cardiac resynchronization therapy.
Br J Hosp Med (Lond). 2017 Oct 2;78(10):594. doi: 10.12968/hmed.2017.78.10.594.
2
National Institute for Health and Care Excellence 2014 guidance on cardiac implantable electronic devices: health economics reloaded.
Europace. 2015 Mar;17(3):339-42. doi: 10.1093/europace/euu384.
3
Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial.希腊心脏再同步治疗的成本效益：基于心力衰竭心脏再同步治疗试验的分析。
Europace. 2011 Nov;13(11):1597-603. doi: 10.1093/europace/eur188. Epub 2011 Aug 6.
4
Perspective on cost-effective utilization of cardiac resynchronization therapy.心脏再同步治疗的成本效益利用视角
J Cardiovasc Electrophysiol. 2013 Jan;24(1):75-6. doi: 10.1111/jce.12007. Epub 2012 Nov 6.
5
Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.轻度心力衰竭患者心脏再同步治疗的经济价值和成本效益：REVERSE 长期随访预测结果。
JACC Heart Fail. 2017 Mar;5(3):204-212. doi: 10.1016/j.jchf.2016.10.014. Epub 2017 Jan 11.
6
Cost-effectiveness of cardiac resynchronisation therapy.心脏再同步治疗的成本效益
Heart. 2012 Dec;98(24):1828-36. doi: 10.1136/heartjnl-2012-301845.
7
The economics of heart failure.心力衰竭的经济学
Heart Fail Clin. 2013 Jan;9(1):93-106. doi: 10.1016/j.hfc.2012.09.005.
8
Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).心脏再同步治疗对无症状至轻度心力衰竭患者的成本效益：来自 REVERSE（心脏再同步治疗可逆转收缩性左心室功能障碍的重构）欧洲队列的研究结果
Eur Heart J. 2011 Jul;32(13):1631-9. doi: 10.1093/eurheartj/ehq408. Epub 2010 Nov 25.
9
Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.延长器械寿命对植入式心脏转复除颤器治疗长期成本的影响：具有 15 年时间范围的建模研究。
Europace. 2013 Oct;15(10):1453-62. doi: 10.1093/europace/eut133. Epub 2013 May 21.
10
Impact of community wealth on use of cardiac-resynchronization therapy with defibrillators for heart failure patients.社区财富对心力衰竭患者使用心脏再同步除颤器治疗的影响。
Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):798-807. doi: 10.1161/CIRCOUTCOMES.112.965509. Epub 2012 Oct 23.
Zotero 插件